Evidence map›Paper›PMID 37714925›Full record

ArticleLeukemia2023

A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML.

Wenxin Du, Zhimei Xia, Zebin Luo, Yichang Chen, Shaowei Bing, Wei Wang, Xingya Zhang, Zhan Zhou, Jingying Zhang, Ji Cao and 5 more

Registry-linked trialAbstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06233526 (Individualized Treatment of Pediatric Relasped and Refractory Acute Myeloid Leukemia Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06233526 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Individualized Treatment of Pediatric Relasped and Refractory Acute Myeloid Leukemia Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test

TypeinterventionalSponsorThe Children's Hospital of Zhejiang University School of MedicineRan2024 to 2025Enrolled60ConditionsAcute Myeloid Leukemia in ChildrenArmsChemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wenxin DuInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Zhimei XiaInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Zebin LuoDivision of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China.
Yichang ChenInnovation Institute for Artificial Intelligence in Medicine, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences and Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, 310018, Hangzhou, China.
Shaowei BingInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Wei WangInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Xingya ZhangInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Zhan ZhouInnovation Institute for Artificial Intelligence in Medicine, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences and Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, 310018, Hangzhou, China.ORCID 0000-0002-2730-5483
Jingying ZhangDivision of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China.
Ji CaoInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Bo YangInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Qiaojun HeInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Xuejing ShaoInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. xjshao@zju.edu.cn.
Xiaojun XuDivision of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China. xuxiaojun@zju.edu.cn.ORCID 0000-0003-1388-2535
Meidan YingInstitute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. mying@zju.edu.cn.ORCID 0000-0003-0039-9683

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273942
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Core Binding Factor Alpha 2 SubunitLeukemia, Myeloid, AcuteGene Expression Regulation, LeukemicGene FusionHumansNeoplasm Recurrence, LocalNuclear Pore Complex ProteinsOncogene Proteins, FusionTranslocation, GeneticCore Binding Factor Alpha 2 Subunitnuclear pore complex protein 98Nuclear Pore Complex ProteinsOncogene Proteins, FusionRUNX1 protein, human

Identifiers

PMID37714925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.